Gossypetin (Flavonol · Antihypertensive · Antioxidant)

Compound	Gossypetin
Chemical class	Polyphenol — Flavonol (8-Hydroxyquercetin)
CAS	489-35-0
Primary source	Hibiscus sabdariffa (calyx)
Key applications	Diuretic support, antihypertensive, antioxidant
Claim strength	Moderate
Typical form	Standardised hibiscus extract

Name origin: From Gossypium (cotton), where it was first isolated, though Hibiscus sabdariffa is the primary commercial source. Traditional use: Hibiscus calyx preparations have been used in West African and South Asian ethnomedicine for diuresis and blood pressure management, with gossypetin as a key contributing flavonol. Research trajectory: Preclinical studies demonstrate ACE-inhibitory and antioxidant activity; clinical evidence is derived largely from hibiscus extract trials rather than isolated gossypetin. Commercial source: Supplied as a constituent of standardised hibiscus calyx extracts; isolated gossypetin remains a research-grade material.

---

Evidence for Gossypetin Applications

Antihypertensive activity: Gossypetin contributes to the ACE-inhibitory fraction of hibiscus calyx extracts. Multiple human RCTs on standardised hibiscus extract show significant reductions in systolic blood pressure in pre-hypertensive and mildly hypertensive populations. Attribution to gossypetin specifically is inferred from in vitro enzyme-inhibition data. Claim strength: Moderate.

Diuretic support: Animal studies show increased urinary output with gossypetin-containing hibiscus preparations, consistent with traditional diuretic use. No dedicated human trials on isolated gossypetin exist. Claim strength: Emerging.

Antioxidant and lipid modulation: In vitro ORAC and DPPH assays confirm strong free-radical scavenging. Animal studies with hibiscus extract report LDL-lowering and hepatoprotective effects; gossypetin is considered a contributor alongside chlorogenic acids and anthocyanins. Claim strength: Moderate.

---

Dosage & Formulator Specification

Gossypetin is not formulated as an isolated ingredient in commercial supplement contexts. Formulators access it via standardised hibiscus calyx extract, typically standardised to 15–30% total anthocyanins and/or total polyphenols, which co-delivers gossypetin alongside hibiscus anthocyanins and chlorogenic acids.

Hibiscus extract doses used in cardiovascular RCTs: 450–600 mg/day of a 10–15% polyphenol extract, taken orally in two divided doses. For antioxidant blending, 150–250 mg of a 25–30% extract per serving is typical.

Gossypetin is heat- and light-sensitive; encapsulation or opaque packaging is recommended. Solubility is limited in water; hydro-ethanolic extraction improves yield. For RTD applications, a water-soluble hibiscus extract should be specified.

---

Frequently Asked Questions — Gossypetin

Is gossypetin the same as hibiscus extract?
No. Gossypetin is one flavonol among many polyphenols in hibiscus calyx, which also contains delphinidin-3-sambubioside, chlorogenic acids, and hydroxycitric acid. Commercially, it is supplied within hibiscus extract rather than as a pure isolate.

What standardisation marker should I specify for hibiscus extract?
For cardiovascular applications, specify 15–25% total polyphenols or 10–15% total anthocyanins by UV. For antioxidant blending, 25–30% total polyphenols is appropriate. HPLC-verified gossypetin content is rarely specified commercially.

Does gossypetin interact with antihypertensive medications?
Hibiscus extracts have demonstrated modest ACE-inhibitory and diuretic activity in clinical trials. Formulators targeting blood pressure management should include standard advisory language regarding concomitant antihypertensive drug use.

What is the stability profile of gossypetin in finished formats?
As a polyhydroxylated flavonol, gossypetin is susceptible to oxidative degradation. Hard capsule or tablet formats with minimal moisture exposure are preferred. RTD beverages require pH optimisation (pH 3.0–3.5) and nitrogen flushing to extend polyphenol shelf life.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery